USPTO 2015–2025 USPTO PatentsView US Corporation

The Translational Genomics Research Institute

USPTO PatentsView assignee record - 105 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, The ranks #3,513 of 49,997 tracked US assignees by granted-patent volume, with 105 patents across 23 technology areas.

#3,513
of 49,997 US assignees by volume
Top 24%
by Innovation Score (45.0/100)
14.1
avg claims per patent
-38%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3513 · US Corporation #3,513 · 105 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MID 105 grants
  • TOP-DECILE #3,513/49,997
  • PHOTO-FINISH Sony Pictures…
  • CPC-FOCUS C12Q · 23 areas
  • INNOV-PAR 45.0/100
  • CLAIMS-RICH 14.1 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -38% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sony Pictures Entertainment Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around The

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows The's Innovation Score is 45.0/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where The's grants concentrate

The Translational Genomics Research Institute is a focused PatentsView assignee: 23 CPC subclasses with 62.9% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2015 (14 grants) versus a trough of 4 in 2023. By volume, The sits between Sony Pictures Entertainment Inc. and Valencell, Inc..

The's three-year grant acceleration

From 2019–2021 to 2022–2024, The Translational Genomics Research Institute moved from 33 to 17 grants (0.52x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,653. See the growth leaderboard.

Who files at The's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows The holds 105 patents at rank #3,514, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near The

By rank, the assignees closest to #3,514 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in The's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for The, neither rank-band nor same-CPC leaders (those blocks stay above).

The's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

051015 20152016201720182019202020212022202320242025 6
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
The Translational Genomics Research Institute patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 14 13.3%
2016 14 13.3%
2017 11 10.5%
2018 10 9.5%
2019 12 11.4%
2020 13 12.4%
2021 8 7.6%
2022 6 5.7%
2023 4 3.8%
2024 7 6.7%
2025partial year 6 5.7%

Which technologies does The Translational Genomics Research Institute patent most?

Top 15 of 23 technology areas

Where it ranks

Overall rank by patents

#3,513

of 49,997 tracked assignees

Innovation Score

45.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

The Translational Genomics Research Institute's patent record in context - here's where to go next.

  • The Translational Genomics Research Institute's lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 62.9% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #3,513 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare The Translational Genomics Research Institute against Sony Pictures Entertainment Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 45.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.